US5767309A - Processes for preparing L!- or D!-homoalanin-4-yl-(methyl)phosphinic acid and salts thereof by racemate resolution - Google Patents

Processes for preparing L!- or D!-homoalanin-4-yl-(methyl)phosphinic acid and salts thereof by racemate resolution Download PDF

Info

Publication number
US5767309A
US5767309A US08/398,216 US39821695A US5767309A US 5767309 A US5767309 A US 5767309A US 39821695 A US39821695 A US 39821695A US 5767309 A US5767309 A US 5767309A
Authority
US
United States
Prior art keywords
acid
salt
methyl
homoalanin
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/398,216
Inventor
Harald Knorr
Gunter Schlegel
Herbert Stark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Hoechst Schering Agrevo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Schering Agrevo GmbH filed Critical Hoechst Schering Agrevo GmbH
Assigned to HOECHST SCHERING AGREVO GMBH reassignment HOECHST SCHERING AGREVO GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KNORR, HARALD, SCHLEGEL, GUNTER, STARK, HERBERT
Priority to US09/049,404 priority Critical patent/US5869668A/en
Application granted granted Critical
Publication of US5767309A publication Critical patent/US5767309A/en
Assigned to BAYER CROPSCIENCE GMBH reassignment BAYER CROPSCIENCE GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AVENTIS CROPSCIENCE GMBH
Assigned to BAYER CROPSCIENCE AG reassignment BAYER CROPSCIENCE AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BAYER CROPSCIENCE GMBH
Assigned to AVENTIS CROPSCIENCE GMBH reassignment AVENTIS CROPSCIENCE GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: HOECHST SCHERING AGREVO GMBH
Assigned to BAYER INTELLECTUAL PROPERTY GMBH reassignment BAYER INTELLECTUAL PROPERTY GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYER CROPSCIENCE AG
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/36Racemisation of optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301Acyclic saturated acids which can have further substituents on alkyl

Definitions

  • DL-Ia DL!-Homoalanin-4-yl(methyl)phosphinic acid
  • DL-Ib ammonium salt thereof
  • the amino-acid derivatives are active in the L form (L-Ia or L-Ib), whereas the relevant enantiomeric D form is virtually inactive (DE-A-2856260).
  • the L form can be obtained by enzymatic transamination.
  • the working up of the transamination solution is technically very elaborate; in addition, large amounts of salt are produced.
  • the pure L form is likewise obtained by starting from D!-valine in several stages, with an enantioselective alkylation of R!-3-isopropyl-2,5-dialkoxy-3,6-dihydropyrazines as key reaction; however, the disadvantages for application on the industrial scale are the difficulty of obtaining the heterocyclic intermediates and the necessity to use organometallic agents.
  • the L form is obtained by asymmetric hydrogenation of N-substituted 2-amino-4- (methyl) (hydroxy)phosphino!butenoic acids (EP-A-238954).
  • J. Org. Chem. 48 (1983) 843-846 relates to the racemization of D-amino acids in acetic acid or other organic carboxylic acids in the presence of catalytic amounts of aliphatic or aromatic aldehydes.
  • U.S. Pat. No. 3,213,106 discloses the racemization of optically active amino acids in water without the addition of strong bases or acids at temperatures of 150°-250° C.; furthermore, according to JP-42-13445, amino acids can be racemized in water and in the presence of an aliphatic aldehyde with metal ion catalysis.
  • the latter racemization methods have the disadvantage that the amino acids are partly decomposed at the stated temperatures or the conversion rate is much too low.
  • the object therefore was to find a racemate resolution process which can be carried out on the industrial scale and with which the disadvantages described above are substantially avoided.
  • the invention relates to a process for preparing L!-homoalanin-4-yl(methyl)phosphinic acid (L acid) and salts thereof or D!-homoalanin-4-yl(methyl)phosphinic acid (D acid) and salts thereof from racemic DL!-homoalanin-4-yl(methyl)phosphinic acid (DL acid) or salts thereof, which comprises
  • the process according to the invention for preparing L!-homoalanin-4-yl(methyl)phosphonic acid and salts thereof is carried out with chiral bases, preferably alkaloid bases such as quinine, cinchonidine and brucine.
  • alkaloid bases such as quinine, cinchonidine and brucine.
  • quinine is particularly advantageous.
  • the enantiomers of the said chiral bases are suitable for preparing D!-homoalanin-4-yl(methyl)phosphinic acid.
  • Suitable mixing partners for the aqueous-organic solvent mixtures are, for example, organic solvents from the group consisting of alcohols such as, for example, methanol, ethanol, n-propanol, i-propanol, n-butanol, i-butanol, sec-butanol and t-butanol, of ketones such as, for example, acetone, methyl ethyl ketone, methyl isobutyl ketone and N-methylpyrrolidone, and combinations of the said solvents. It is also possible with comparatively small amounts of solvent, i.e. using highly concentrated solutions, to use water as sole solvent.
  • the optimal temperature for the crystallization depends on the chiral base, the solvent, the concentration of the salt, the amount of the chiral base and the crystallization rate. It is, as a rule, advantageous to carry out the crystallization at temperatures of 0°-100° C., preferably 0°-85° C., in particular at 15°-75° C.
  • Suitable and preferred solvent mixtures are composed of water and alcohols, for example t-butanol:water in the ratio of, for example, 20:80 to 90:10, preferably 50:50 to 85:15, in particular 70:30 to 85:15, or isopropanol:water in the ratio of 20:80 to 90:10, preferably 50:50 to 90:10, in particular 70:30 to 85:15.
  • the latter ratios of amounts preferably apply to carrying out the crystallization at temperatures of 0°-85° C., in particular 15°-75° C.
  • the liberation of the acid (L-Ia) from the diastereomeric salt of the crystals can take place in analogy to customary methods, for example by neutralization with an organic or inorganic acid, where appropriate in a suitable solvent.
  • the metathesis into another salt can take place by reaction with an excess of an inorganic base which contains the desired cation, or with an organic base (for example amine base) or ammonia when optionally substituted ammonium salts of (L-Ia) are to be prepared.
  • Preparation of the ammonium salt (L-Ib) which can be used satisfactorily as herbicide, by metathesis with ammonia is preferred.
  • the reaction with ammonia can be carried out, for example, by dissolving the crystals in a suitable solvent such as methanol and passing in ammonia or adding a solution of ammonia in a solvent, for example methanol again, in excess, and precipitating the ammonium salt (L-Ib).
  • a suitable solvent such as methanol
  • a solution of ammonia in a solvent for example methanol again, in excess
  • precipitating the ammonium salt (L-Ib) precipitating the ammonium salt (L-Ib).
  • the mother liquor which contains the chiral base can then be returned to the next batch.
  • the undesired D isomer (D-Ia) or the salt thereof for example the salt of (D-Ia) with the chiral base, is racemized, and the resulting racemic compound (DL-Ia) or salt thereof is used for the racemate resolution according to the invention.
  • the racemization may take place separately or with the racemate resolution:
  • Suitable for carrying out the racemization of the D isomer after the crystallized salt of the L isomer has been separated out are the abovementioned processes (see also Example C in the "Comparative Examples” section hereinafter).
  • the known processes usually have further disadvantages, for example that the racemization must take place in the presence of acids.
  • the addition of organic acids has considerable technical disadvantages for the process when the known method is applied to the racemization of the salt of the D isomer and of the chiral base which results according to the invention in the mother liquor of the crystallization stage.
  • Addition of acid means, for example, a change of the solvent, for which reason the racemization solution cannot be returned directly to the next crystallization batch without altering the crystallization conditions.
  • racemization in the presence of the known aldehydes does not as a rule take place without the addition of acids, i.e. if the intention is to carry out the racemization with the aldehydes in neutral or weakly basic or even weakly acidic aqueous medium.
  • the invention therefore also relates to a novel process for the racemization of optically active amino acids, preferably amino acids of the formula (D-Ia) and derivatives thereof, which comprises reacting the optically active amino acids in the presence of six-membered (hetero)aromatic aldehydes which have a hydroxyl group in position 2 with respect to the aldehyde group and electron-attracting radicals such as, for example, NO 2 , CN, CF 3 and SO 3 H, in particular NO 2 , in position 3 or 5 with respect to the aldehyde group and are further substituted where appropriate, in aqueous or aqueous-organic medium.
  • six-membered (hetero)aromatic aldehydes which have a hydroxyl group in position 2 with respect to the aldehyde group and electron-attracting radicals such as, for example, NO 2 , CN, CF 3 and SO 3 H, in particular NO 2 , in position 3 or 5 with respect to the aldehyde group
  • racemization according to the invention takes place without the addition of inorganic or organic acids. Racemization in neutral or weakly basic or weakly acidic medium, for example at pH 4-9, in particular at pH 5-8, is preferred.
  • the racemization is, as a rule, carried out at temperatures of 0°-120° C., preferably 30°-85° C., in particular 35°-75° C., depending on the reactivity of the aldehyde.
  • Preferred aldehydes for the racemization are salicylaldehydes activated on the phenyl ring by electron-attracting radicals in position 3 or 5, for example nitro groups, and are further substituted where appropriate, for example 5-nitrosalicylaldehyde or 3,5-dinitrosalicylaldehyde.
  • pyridinealdehydes for example pyridoxal, which may, depending on the substitution pattern, also be immobilized on an inorganic or organic support.
  • Suitable amino acids are the customary optically active amino acids and salts thereof, for example D- or L-alanine, substituted D- or L-alanines, substituted glycines such as phenylglycine or hydroxyphenylglycine, and D- or L-leucines etc. and the amino-acid derivatives such as (D-or L-Ia).
  • the amount of aldehydes used can vary within wide limits and can easily be optimized in preliminary experiments.
  • the aldehydes are preferably used in less than the stoichiometric amount based on the amino acid or salt thereof, in particular in catalytic amounts.
  • the amounts of the particular aldehyde are in the range from 0.01 mole to 0.1 mole per mole of amino acid or salt thereof used. If a very small amount of aldehyde is used, the conversion takes place too slowly for practical purposes. The use of excessively large amounts of aldehyde may impair further processing of the mixture and also appears to have little sense from the economic viewpoint.
  • a particular advantage of the racemization according to the invention is that it can be carried out at considerably lower temperatures than was to be expected.
  • the conversion not only takes place at the temperatures of 80°-150° C. used in strongly acidic media but can also be carried out at temperatures below 80° C., preferably 35°-75° C., in particular 40°-70° C.
  • these low temperatures for the racemate resolution of (DL-Ia) using chiral bases make it possible to carry out the crystallization of the salt of (L-Ia) and of the chiral base at the same time as the racemization of the salt of (D-Ia) in one mixture.
  • One possibility comprises, after the crystallization in stage b) of the process according to the invention, heating the mother liquor, which essentially contains the diastereomeric salt of (D-Ia) and residues of the diastereomeric salt of (L-Ia), in the presence of one of the said aldehydes, carrying out the racemization at temperatures of 0°-120° C., preferably 30°-85° C., in particular 35°-75° C.
  • the salt of the racemized amino acid and of the chiral base can then be returned directly, i.e. without working up and without changing the solvent, to the next crystallization batch.
  • a combined procedure (alternative 1) as batch process or as continuous process for preparing the ammonium salt (L-Ib) starting from the ammonium salt (DL-Ib) comprises, for example,
  • stage (1) Temperatures of 20°-100° C. are advantageous in stage (1), whereas the step according to stage (2) is beneficially carried out at 0°-85° C., preferably at 15°-75° C.
  • stage (3) should be appropriate for the reactivity of the aldehyde.
  • stage (4) can preferably be carried out at temperatures of 0°-60° C.
  • the racemization is carried out in the same stage as the crystallization of the diastereomeric salt of (L-Ia) .
  • the conditions for the crystallization in respect of solvent and temperature are then inevitably consistent with those for the racemization; this restricts the choice of the racemization processes and, in the case of the mentioned racemization with aldehydes, the choice of the possible aldehydes.
  • this combined process is not practicable using the conventional processes in the presence of acids and aldehydes but can be carried out using the said inventive process for racemization using specific aldehydes without the addition of acids.
  • the inventive variant of the combined process comprises reacting a mixture of the diastereomeric salts of D acid and L acid and of the chiral base, dissolved in an aqueous or aqueous-organic solvent in which the salt of the D acid has a higher solubility than the salt of the L acid, at temperatures of 0°-85° C., preferably of 30°-85° C. in the presence of an aldehyde, the temperature being set sufficiently low for the salt of the L acid and of the chiral base to crystallize out at the same time.
  • the preferred combined procedure (alternative 2), as batch process or as continuous process for the preparation of the ammonium salt (L-Ib) starting from the ammonium salt (DL-Ib), comprises, for example,
  • Process steps (1') and (3') substantially correspond to process steps (1) and (4) from the combined process already mentioned above (alternative 1).
  • the process step according to stage (1') is advantageously carried out at temperatures of 20°-100° C.
  • the step according to stage (2') is beneficially carried out at the temperature at which the diasteromeric salt of (L-Ia) crystallizes out but the racemization of the undesired (D-Ia) still takes place sufficiently quickly.
  • Stage (3') is advantageously carried out at temperatures of 0°-60° C.
  • a diagrammatic comparison of alternatives 1 and 2 shows, taking the example of the racemate resolution of (L-Ib), the saving of a process stage in alternative 2 (see Table 1):
  • Suitable solvents for the process stages described above are the solvents already mentioned for the crystallization stage.
  • An advantageous procedure comprises using the same solvent system in all the process steps. However, it is sometimes also sensible to vary the properties of the solvent system simply by adding another solvent to the solvent from the previous stage.
  • L salt means the salt of (L-Ia), (D-Ia) and (D,L-Ia), respectively, and of the chiral base.
  • the diastereomeric L salt precipitates slowly at 48° C. and below.
  • the mixture is allowed to reach room temperature over the course of 6 hours, and the solid is filtered off with suction, washed with a little tert-butanol/water (80:20) and dried in vacuo at 60° C.
  • the mixture is stirred for 9 to 10 hours, during which the L salt slowly precipitates.
  • the mixture is allowed to reach room temperature over the course of 6 hours, and the solid is filtered off with suction, washed with tert-butanol/water (80:20) and dried in vacuo at 60° C.
  • the mother liquor is added to another batch at 70° C.
  • the mother liquor which essentially contains the (-)quinine, is added to another batch.
  • A) 90 g of tert-butanol are added to 2.7 g of DL!-homoalanin-4-yl(methyl)phosphinic acid (0.015 mole), 5.0 g of ammonium (+)-3-bromocamphor-8-sulfonate (0.015 mole) in 10 g of demineralized water at 75° C. in such a way that the temperature is kept at 75° C.
  • the mixture is heated under reflux for 1 hour and then slowly allowed to reach room temperature. Precipitated crystals are filtered off with suction, washed and dried in vacuo at 50° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Processes for preparing [L]- or [D]-homoalanin-4-yl-(methyl)phosphinic acid and salts thereof by racemate resolution The title compounds are obtained by racemate resolution of D,L-homoalanin-4-yl (methyl)phosphinic acid via precipitation of one of the diastereomeric salts using chiral bases such as quinine or cinchonine. It is possible to increase the yield of desired enantiomer by transformed racemate resolution when the precipitation of the diastereomeric salt takes place with the racemization of the undesired enantiomer in the presence of (hetero)aromatic aldehydes. The racemization method is also suitable for structurally different optically active amino acids.

Description

DL!-Homoalanin-4-yl(methyl)phosphinic acid (DL-Ia) and the ammonium salt thereof (DL-Ib) are amino-acid derivatives with herbicidal activity (DE-A-27 17 440). The amino-acid derivatives are active in the L form (L-Ia or L-Ib), whereas the relevant enantiomeric D form is virtually inactive (DE-A-2856260). ##STR1##
In order to be able to use the pure active substance, special processes have been developed to prepare L!-homoalanin-4-yl(methyl)phosphinic acid and the ammonium salt thereof.
According to DE-A-3 920 570 and DE-A-3 923 650, the L form can be obtained by enzymatic transamination. However, the working up of the transamination solution is technically very elaborate; in addition, large amounts of salt are produced.
According to EP-A-224 880, the pure L form is likewise obtained by starting from D!-valine in several stages, with an enantioselective alkylation of R!-3-isopropyl-2,5-dialkoxy-3,6-dihydropyrazines as key reaction; however, the disadvantages for application on the industrial scale are the difficulty of obtaining the heterocyclic intermediates and the necessity to use organometallic agents.
In addition, the L form is obtained by asymmetric hydrogenation of N-substituted 2-amino-4- (methyl) (hydroxy)phosphino!butenoic acids (EP-A-238954).
It is likewise possible to prepare (L-Ia) starting from L-vinylglycine or (subst.) L-4-vinyl-1,3-oxazolidin-5-ones and methanephosphonous monoesters (EP-A-546566 and EP-A-346658); however, the chiral precursors are not easy to obtain.
Furthermore, processes using methanephosphonous diesters are known (EP-A-508298 and EP-A-530506); however, the required phosphorous component is not available in large amounts, which impedes implementation of this process on the large scale.
Practicable separation of the racemic mixture DL-Ia! into the pure enantiomers by the "classical" precipitation method utilizing differences in the solubilities of diastereomeric salts has not been disclosed to date. Some processes in which racemates can be separated with the aid of chiral compounds via diastereomeric salts have been described for structurally different amino acids. Of particular interest in this connection are processes in which the precipitation of a diastereomeric salt of the desired enantiomer is combined with racemization of the undesired enantiomer.
For example, Bull. Chim. Soc. Jap. 56 (1983) 3744-3747 describes the preparation of D!-phenylglycine from DL!-phenylglycine with the aid of d!-camphor-10-sulfonic acid as salt former in the presence of acetic acid and salicylaldehyde as racemizing agent in 68% yield and an optical purity of 95.9%.
Shiraiwa et al. describe in Chem. Lett. 1990, 233 et seq. a process for preparing N-methyl- D! -2-phenylglycine from N-methyl- DL!-2-phenylglycine using l!-camphorsulfonic acid in butanoic acid without the addition of aldehydes or ketones. In this case the salt of the D-amino acid precipitates while the L-amino acid racemizes. Triethylamine is subsequently used to liberate the D-amino acid from the diastereomeric salt in yields of 71-77%.
U.S. Pat. No. 4,647,692 describes the racemate resolution of the amino acids 4-hydroxyphenylglycine and 3,4-dihydroxyphenylglycine by precipitation using (+)-3-bromocamphor-10-sulfonic acid in the presence of ketones and organic acids such as acetic acid. This method is also recommended in general form for racemate resolution of DL-Ia.
Independently of the above precipitation methods which combine racemate resolution and racemization of the incorrect enantiomer, publications which describe only racemization methods are known:
J. Org. Chem. 48 (1983) 843-846 relates to the racemization of D-amino acids in acetic acid or other organic carboxylic acids in the presence of catalytic amounts of aliphatic or aromatic aldehydes.
U.S. Pat. No. 3,213,106 discloses the racemization of optically active amino acids in water without the addition of strong bases or acids at temperatures of 150°-250° C.; furthermore, according to JP-42-13445, amino acids can be racemized in water and in the presence of an aliphatic aldehyde with metal ion catalysis. The latter racemization methods have the disadvantage that the amino acids are partly decomposed at the stated temperatures or the conversion rate is much too low.
Application of the precipitation methods mentioned hereinbefore to the separation of DL!-homoalanin-4-yl-(methyl)phosphonic acid using d- or l-camphorsulfonic acid or derivatives thereof proves to be impracticable.
For example, it is not possible to separate out the diastereomeric salt of L!-homoalanin-4-yl(methyl)phosphinic acid and d!-3-bromocamphor-10-sulfonic acid, as is evident from Comparative Examples A) and B) (see section "Comparative Examples").
The object therefore was to find a racemate resolution process which can be carried out on the industrial scale and with which the disadvantages described above are substantially avoided.
The invention relates to a process for preparing L!-homoalanin-4-yl(methyl)phosphinic acid (L acid) and salts thereof or D!-homoalanin-4-yl(methyl)phosphinic acid (D acid) and salts thereof from racemic DL!-homoalanin-4-yl(methyl)phosphinic acid (DL acid) or salts thereof, which comprises
a) reacting DL acid or salt thereof with a chiral base,
b) allowing the salt of the L acid or D acid and of the chiral base to crystallize out of a solution of the resulting mixture of the diastereomeric salts of D acid, L acid and the chiral base in an aqueous or aqueous-organic solvent in which the salt of the D acid or of the L acid has a higher solubility than the salt of the L acid or D acid, respectively (racemate resolution) and
c) in the case where the free L acid or D acid is prepared, neutralizing the resulting salt with an acid, or in the case where a salt other than that obtained according to b) is prepared, carrying out a metathesis.
The process according to the invention for preparing L!-homoalanin-4-yl(methyl)phosphonic acid and salts thereof is carried out with chiral bases, preferably alkaloid bases such as quinine, cinchonidine and brucine. The use of quinine is particularly advantageous.
The enantiomers of the said chiral bases, for example quinidine and cinchonine, are suitable for preparing D!-homoalanin-4-yl(methyl)phosphinic acid.
Because of the greater economic importance of the L acid, the process routes are described hereinafter for the example of the preparation of L acid. The processes can be used analogously to prepare the D acid by using the enantiomeric chiral bases.
In order to reduce the solubility of diastereomeric salts of the L! form compared with the solubility in pure aqueous solutions it is possible to use, for example, solvent mixtures composed of water and organic solvents which are miscible with water in the particular mixing ratio used. Suitable mixing partners for the aqueous-organic solvent mixtures are, for example, organic solvents from the group consisting of alcohols such as, for example, methanol, ethanol, n-propanol, i-propanol, n-butanol, i-butanol, sec-butanol and t-butanol, of ketones such as, for example, acetone, methyl ethyl ketone, methyl isobutyl ketone and N-methylpyrrolidone, and combinations of the said solvents. It is also possible with comparatively small amounts of solvent, i.e. using highly concentrated solutions, to use water as sole solvent.
The use of i-propanol or t-butanol in combination with water proves particularly advantageous.
The optimal temperature for the crystallization depends on the chiral base, the solvent, the concentration of the salt, the amount of the chiral base and the crystallization rate. It is, as a rule, advantageous to carry out the crystallization at temperatures of 0°-100° C., preferably 0°-85° C., in particular at 15°-75° C. Suitable and preferred solvent mixtures are composed of water and alcohols, for example t-butanol:water in the ratio of, for example, 20:80 to 90:10, preferably 50:50 to 85:15, in particular 70:30 to 85:15, or isopropanol:water in the ratio of 20:80 to 90:10, preferably 50:50 to 90:10, in particular 70:30 to 85:15. The latter ratios of amounts preferably apply to carrying out the crystallization at temperatures of 0°-85° C., in particular 15°-75° C.
The liberation of the acid (L-Ia) from the diastereomeric salt of the crystals can take place in analogy to customary methods, for example by neutralization with an organic or inorganic acid, where appropriate in a suitable solvent. The metathesis into another salt can take place by reaction with an excess of an inorganic base which contains the desired cation, or with an organic base (for example amine base) or ammonia when optionally substituted ammonium salts of (L-Ia) are to be prepared. Preparation of the ammonium salt (L-Ib), which can be used satisfactorily as herbicide, by metathesis with ammonia is preferred. The reaction with ammonia can be carried out, for example, by dissolving the crystals in a suitable solvent such as methanol and passing in ammonia or adding a solution of ammonia in a solvent, for example methanol again, in excess, and precipitating the ammonium salt (L-Ib). The mother liquor which contains the chiral base can then be returned to the next batch.
In a preferred procedure for the process according to the invention, the undesired D isomer (D-Ia) or the salt thereof, for example the salt of (D-Ia) with the chiral base, is racemized, and the resulting racemic compound (DL-Ia) or salt thereof is used for the racemate resolution according to the invention.
Processes suitable in principle for the racemization of (D-Ia) are those with which other amino acids can also be racemized. For example, the references already mentioned above, Bull. Chim. Soc. Jap. 56 (1983) 3744-3747, Chem. Lett. 1990, 233 et seq. and J. Org. Chem. 48 (1983) 843-846 disclose the catalysis of racemizations of optically active amino acids by aldehydes in organic acids.
The racemization may take place separately or with the racemate resolution:
a) Suitable for carrying out the racemization of the D isomer after the crystallized salt of the L isomer has been separated out are the abovementioned processes (see also Example C in the "Comparative Examples" section hereinafter). Apart from the additional process stages in the case of separate racemization, however, the known processes usually have further disadvantages, for example that the racemization must take place in the presence of acids. The addition of organic acids has considerable technical disadvantages for the process when the known method is applied to the racemization of the salt of the D isomer and of the chiral base which results according to the invention in the mother liquor of the crystallization stage. Addition of acid means, for example, a change of the solvent, for which reason the racemization solution cannot be returned directly to the next crystallization batch without altering the crystallization conditions.
b) If, furthermore, the racemization of the D isomer is to take place in the same reaction mixture at the same time as the crystallization, according to the invention, of the salt of the L isomer and of the chiral base, the known racemization methods can no longer be applied or are not practicable industrially, as is evident from Comparative Example D hereinafter. Although the diastereomeric salt of (D-Ia) and of the chiral base, in this case quinine, can be smoothly racemized in acetic acid in the presence of salicylaldehyde (Comparative Example C), it is impossible to crystallize the diastereomeric salt of (L-Ia) in acetic acid medium (Comparative Example D).
The organic acids added in the known racemization methods must for the abovementioned reasons be avoided in the preferred combined crystallization process according to the invention. Racemization in the presence of the known aldehydes does not as a rule take place without the addition of acids, i.e. if the intention is to carry out the racemization with the aldehydes in neutral or weakly basic or even weakly acidic aqueous medium.
Surprisingly, our experiments have shown that the racemization takes place even in such media when certain aldehydes are used.
The invention therefore also relates to a novel process for the racemization of optically active amino acids, preferably amino acids of the formula (D-Ia) and derivatives thereof, which comprises reacting the optically active amino acids in the presence of six-membered (hetero)aromatic aldehydes which have a hydroxyl group in position 2 with respect to the aldehyde group and electron-attracting radicals such as, for example, NO2, CN, CF3 and SO3 H, in particular NO2, in position 3 or 5 with respect to the aldehyde group and are further substituted where appropriate, in aqueous or aqueous-organic medium.
The racemization according to the invention takes place without the addition of inorganic or organic acids. Racemization in neutral or weakly basic or weakly acidic medium, for example at pH 4-9, in particular at pH 5-8, is preferred.
The racemization is, as a rule, carried out at temperatures of 0°-120° C., preferably 30°-85° C., in particular 35°-75° C., depending on the reactivity of the aldehyde.
Preferred aldehydes for the racemization are salicylaldehydes activated on the phenyl ring by electron-attracting radicals in position 3 or 5, for example nitro groups, and are further substituted where appropriate, for example 5-nitrosalicylaldehyde or 3,5-dinitrosalicylaldehyde.
It is also possible, for example, to use analogous heteroaromatic aldehydes in place of the aromatic aldehydes. It is worth mentioning in this connection pyridinealdehydes, for example pyridoxal, which may, depending on the substitution pattern, also be immobilized on an inorganic or organic support.
Suitable amino acids are the customary optically active amino acids and salts thereof, for example D- or L-alanine, substituted D- or L-alanines, substituted glycines such as phenylglycine or hydroxyphenylglycine, and D- or L-leucines etc. and the amino-acid derivatives such as (D-or L-Ia).
The amount of aldehydes used can vary within wide limits and can easily be optimized in preliminary experiments. The aldehydes are preferably used in less than the stoichiometric amount based on the amino acid or salt thereof, in particular in catalytic amounts. As a rule, the amounts of the particular aldehyde are in the range from 0.01 mole to 0.1 mole per mole of amino acid or salt thereof used. If a very small amount of aldehyde is used, the conversion takes place too slowly for practical purposes. The use of excessively large amounts of aldehyde may impair further processing of the mixture and also appears to have little sense from the economic viewpoint.
A particular advantage of the racemization according to the invention is that it can be carried out at considerably lower temperatures than was to be expected. The conversion not only takes place at the temperatures of 80°-150° C. used in strongly acidic media but can also be carried out at temperatures below 80° C., preferably 35°-75° C., in particular 40°-70° C. In contrast to the conventional methods mentioned, these low temperatures for the racemate resolution of (DL-Ia) using chiral bases make it possible to carry out the crystallization of the salt of (L-Ia) and of the chiral base at the same time as the racemization of the salt of (D-Ia) in one mixture.
The various possibilities for carrying out the racemate resolution according to the invention and the racemization of the acid (D-Ia) or salt thereof according to the invention are explained below.
One possibility comprises, after the crystallization in stage b) of the process according to the invention, heating the mother liquor, which essentially contains the diastereomeric salt of (D-Ia) and residues of the diastereomeric salt of (L-Ia), in the presence of one of the said aldehydes, carrying out the racemization at temperatures of 0°-120° C., preferably 30°-85° C., in particular 35°-75° C. The salt of the racemized amino acid and of the chiral base can then be returned directly, i.e. without working up and without changing the solvent, to the next crystallization batch.
A combined procedure (alternative 1) as batch process or as continuous process for preparing the ammonium salt (L-Ib) starting from the ammonium salt (DL-Ib) comprises, for example,
(1) reacting ammonium DL!-homoalanin-4-yl(methyl)phosphinate with a chiral base in a solvent mixture of water and an organic solvent which solubilizes the ammonium DL!-homoalanin-4-yl(methyl)phosphinate, and removing the liberated ammonia, then
(2) at temperatures of 0°-85° C. allowing the diastereomeric salt of L!-homoalanin-4-yl(methyl)phosphinic acid and of the chiral base to crystallize out of a solvent mixture of water and an organic solvent, and isolating it, for example by filtration with suction, and subsequently
(3) heating the mother liquor from the crystals, which essentially contains the other diastereomeric salt of the D!-amino acid and residues of the diastereomeric salt of the L!-amino acid, in the presence of a (hetero)aromatic aldehyde at temperatures of 20°-120° C. and, after the racemization, passing the resulting solution to the next crystallization batch (2) and
(4) reacting the diastereomeric salt of L!-homoalanin-4-yl(methyl)phosphonic acid and of the chiral base from stage (2) in the mixture of water and an organic solvent or in the organic solvent itself with ammonia, whereupon ammonium L!-homoalanin-4-yl-(methyl)phosphinate (L-Ib) precipitates, isolating the precipitated ammonium salt (L-Ib), for example by filtration with suction, and returning the mother liquor, which essentially contains the chiral base, to stage (1) of the next batch.
It is important for optimization of the combined process to adapt the temperatures to the particular process step. Temperatures of 20°-100° C. are advantageous in stage (1), whereas the step according to stage (2) is beneficially carried out at 0°-85° C., preferably at 15°-75° C. The temperature in stage (3) should be appropriate for the reactivity of the aldehyde. The process according to stage (4) can preferably be carried out at temperatures of 0°-60° C.
In another possibility, which is particularly preferred, the racemization is carried out in the same stage as the crystallization of the diastereomeric salt of (L-Ia) . The conditions for the crystallization in respect of solvent and temperature are then inevitably consistent with those for the racemization; this restricts the choice of the racemization processes and, in the case of the mentioned racemization with aldehydes, the choice of the possible aldehydes. As already mentioned above, this combined process is not practicable using the conventional processes in the presence of acids and aldehydes but can be carried out using the said inventive process for racemization using specific aldehydes without the addition of acids.
The inventive variant of the combined process comprises reacting a mixture of the diastereomeric salts of D acid and L acid and of the chiral base, dissolved in an aqueous or aqueous-organic solvent in which the salt of the D acid has a higher solubility than the salt of the L acid, at temperatures of 0°-85° C., preferably of 30°-85° C. in the presence of an aldehyde, the temperature being set sufficiently low for the salt of the L acid and of the chiral base to crystallize out at the same time.
It is possible in principle with the preferred combined process (racemate resolution and racemization) to convert (DL-Ia) 100% into (L-Ia). Suitable for the preferred process are the abovementioned chiral bases and the six-membered (hetero) aromatic aldehydes which have a hydroxyl group in position 2 with respect to the aldehyde group and electron-attracting radicals in position 3 or 5 with respect to the aldehyde group, in particular the bases and aldehydes mentioned as preferred.
The preferred combined procedure (alternative 2), as batch process or as continuous process for the preparation of the ammonium salt (L-Ib) starting from the ammonium salt (DL-Ib), comprises, for example,
(1') reacting ammonium DL!-homoalanin-4-yl(methyl)phosphinate with a chiral base in a solvent mixture of water and an organic solvent which solubilizes the ammonium DL!-homoalanin-4-yl(methyl)phosphinate, and removing the ammonia, then
(2') reacting with an aromatic aldehyde at temperatures of 0°-85° C., preferably of 30°-85° C. in the presence of a solvent mixture of water and organic solvent and, at the same time, allowing the diastereomeric salt of L!-homoalanin-4-yl(methyl)phosphinic acid and of the chiral base to crystallize out, isolating the crystals, for example by filtration with suction, and adding the mother liquor to stage (2') of the next batch and
(3') reacting the diastereomeric salt of L!-homoalanin-4-yl(methyl)phosphinic acid and of the chiral base from stage (2') in the mixture of water and an organic solvent or in the organic solvent itself with ammonia, moreover filtering the precipitated ammonium L!-homoalanin-4-yl(methyl)phosphinate with suction, and returning the mother liquor, which essentially contains the chiral base, to stage (1') of the next batch.
For the process to succeed it is important that the temperatures are adapted to the particular process step. Process steps (1') and (3') substantially correspond to process steps (1) and (4) from the combined process already mentioned above (alternative 1). The process step according to stage (1') is advantageously carried out at temperatures of 20°-100° C., whereas the step according to stage (2') is beneficially carried out at the temperature at which the diasteromeric salt of (L-Ia) crystallizes out but the racemization of the undesired (D-Ia) still takes place sufficiently quickly. Stage (3') is advantageously carried out at temperatures of 0°-60° C.
A diagrammatic comparison of alternatives 1 and 2 shows, taking the example of the racemate resolution of (L-Ib), the saving of a process stage in alternative 2 (see Table 1):
              TABLE 1                                                     
______________________________________                                    
No.    Alternative 1    Alternative 2                                     
______________________________________                                    
(1)    (DL-Ib) + chiral base                                              
                        (DL-Ib) + chiral base                             
(2)    Removal of NH.sub.3, where                                         
                        Removal of NH.sub.3, where                        
       appropriate change                                                 
                        appropriate change                                
       solvent          solvent                                           
(3)    Crystallization (race-                                             
                        Crystallization (race-                            
       mate resolution) mate resolution) and                              
                        reaction with aldehyde                            
(4)    Filtration       Filtration                                        
                        Mother liquor back to                             
                        (3)                                               
(5)    Dissolve crystals and                                              
                        Dissolve crystals and                             
       react with NH.sub.3                                                
                        react with NH.sub.3                               
(6)    Filter off product                                                 
                        Filter off product                                
       (L-Ib), mother liquor                                              
                        (L-Ib), mother liquor                             
       back to (1)      back to (1)                                       
(7)    Heat mother liquor from                                            
       (4) with aldehyde and                                              
       back to (3)                                                        
______________________________________                                    
 Re Table 1: (No.) = number of the process operation                      
It is possible to carry out the individual process steps batchwise or else continuously. Mother liquors resulting from the use are preferably returned to the complete process in order to keep losses of yield small.
Suitable solvents for the process stages described above are the solvents already mentioned for the crystallization stage. An advantageous procedure comprises using the same solvent system in all the process steps. However, it is sometimes also sensible to vary the properties of the solvent system simply by adding another solvent to the solvent from the previous stage.
EXAMPLES
In the following Examples, quantity and percentage data are based on weight unless otherwise indicated. The names "L salt", "D salt" and "D,L salt" mean the salt of (L-Ia), (D-Ia) and (D,L-Ia), respectively, and of the chiral base.
Example 1
1.1 39.6 g of 99.8% pure ammonium DL!-homoalanin-4-yl(methyl)phosphinate (0.2 mole) and 65.5 g of (-)quinine (99% pure) (0.2 mole) are heated to reflux in 210.8 g of water. Subsequently 22.6 g of aqueous ammonia are removed by applying a reduced pressure of 100 mbar. At 70° C., 766.4 g of tert-butanol and then 3.38 g of 5-nitrosalicylaldehyde (0.02 mole) are added, and the clear solution is seeded at 50° C. with L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt. The diastereomeric L salt precipitates slowly at 48° C. and below. The mixture is allowed to reach room temperature over the course of 6 hours, and the solid is filtered off with suction, washed with a little tert-butanol/water (80:20) and dried in vacuo at 60° C. This results in 41.0 g of L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt with a purity of L salt:D salt of 98.7:1.3.
1.2 The mother liquor from Example 1.1 is refluxed for 9 hours (sample measurement L:D=50.6:49.4) and added to another 0.2 mole batch in analogy to Example 1.1 at 70° C. (amount used about 0.319 mole of DL! salt). Crystallization is allowed to occur, and 97.3 g of L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt are obtained with a purity of L salt:D salt of 99.5:0.5 (corresponding to 60% of theory). The mother liquor can in turn be added to another batch. The crystals are taken up in 97.3 g of methanol, and 27.8 g of methanolic ammonia (17.7% strength) (0.29 mole) are added; the crystals which have formed are then filtered off. 36.2 g of ammonium L!-homoalanin-4-yl(methyl)phosphinate are obtained with an optical purity of L:D=99.5:0.5.
This corresponds to an isolated yield of 57.0% of theory based on 0.319 mole of DL salt. The mother liquor from these crystals, which essentially contains the (-)quinine, is added to another batch.
Example 2
39.6 g of 99.8% pure ammonium DL!-homoalanin-4-yl(methyl)phosphinate (0.2 mole) and 65.5 g of (-)quinine (99% pure) (0.2 mole) are heated in 210.8 g of water; subsequently 24.0 g of aqueous ammonia are removed by applying a reduced pressure of 100 mbar. At 70° C., 766.4 g of tert-butanol and then 4.3 g of 3,5-dinitrosalicylaldehyde (0.02 mole) are added, the mixture is cooled to 50° C. and the clear solution is seeded with L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt. The mixture is stirred for 9 to 10 hours, during which the L salt slowly precipitates. The mixture is allowed to reach room temperature over the course of 6 hours, and the solid is filtered off with suction, washed with tert-butanol/water (80:20) and dried in vacuo at 60° C. This results in 86.5 g of L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt with a purity of L salt:D salt of 99.5:0.5. This corresponds to a yield of 85.1% of theory. The mother liquor is added to another batch at 70° C. The crystals are taken up in 86.5 g of methanol, 24.7 g of methanolic ammonia (17.7% strength) (0.258 mole) are added, and the crystals which form are filtered off. 32.2 g of ammonium L!-homoalanin-4-yl(methyl)phosphinate are obtained with an optical purity of L:D=99.9:1.0. This corresponds to an isolated yield of 80.5% of theory. The mother liquor, which essentially contains the (-)quinine, is added to another batch.
Example 3
3.5 g of ammonium DL!-homoalanin-4-yl (methyl)phosphinate (0.019 mole) and 6.2 g of (-)quinine (0.019 mole) are dissolved in 18.2 g of water at 50° C., and 27.4 g of hot acetone are added. A clear solution is obtained at 50° C. It is allowed to cool slowly while seeding the clear solution with L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt, and crystallization is allowed to occur. The solid is filtered off with suction at 20° C. and washed with a little acetone, and the filter cake is dried at 60° C. in vacuo. 4.0 g of L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt which contains L-amino acid portion and D-amino acid portion in the enantiomeric ratio of 99.8:0.2 are obtained. This corresponds to a yield of 83.3% of theory based on the use of L form, and 41.7% of theory based on D,L mixture used.
Example 4
3.5 g of ammonium DL!-homoalanin-4-yl(methyl)phosphinate (0.019 mole) and 6.2 g of (-)quinine (0.019 mole) are dissolved in 18.2 g of water at 50° C., and 103.1 g of hot isopropanol are added. A clear solution is obtained at 50° C. It is allowed to cool slowly while seeding the clear solution with L!-homoalanin-4-yl (methyl)phosphinic acid/quinine salt, and crystallization is allowed to occur. The solid is filtered off with suction at 20° C. and washed with a little acetone, and the filter cake is dried at 60° C. in vacuo. 4.2 g of L!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt which contains L-amino acid portion and D-amino acid portion in the enantiomeric ratio of 99.8:0.2 are obtained. This corresponds to a yield of 86.3% of theory based on the use of L form, and 43.2% of theory based on D,L mixture used.
Example 5
1.1 g of D!-homoalanin-4-yl(methyl)phosphinic acid (D:L=99.5:0.5) (0.006 mole), 2.0 g of quinine (0.006 mole) and 0.13 g of 3,5-dinitrosalicylaldehyde (0.0006 mole) are dissolved in 5.2 g of water and 23.0 g of tert-butanol and stirred at 40° C. for 23 hours. DL!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt which contains D-amino acid portion and L-amino acid portion in the enantiomer ratio of 50.2:49.8 is obtained.
Example 6
0.8 g L!-tert-leucine (99% pure, 0.006 mole), 2.0 g of quinine (0.006 mole) and 0.13 g of 3,5-dinitrosalicylaldehyde (0.0006 mole) are dissolved in 5.2 g of water and 23.0 g of tert-butanol and stirred at 50° C. for 24 hours. DL!-tert-leucine which contains D-amino acid portion and L-amino acid portion in the enantiomer ratio of 50.9:49.1 is obtained.
Example 7
3.44 g of DL!-homoalanin-4-yl(methyl)phosphinic acid and 5.6 g of cinchonine (0.019 mole) are dissolved in 27 ml of water at 50° C., and 243 g of tert-butanol are added hot. The solution is seeded with D!-homoalanin-4-yl(methyl)phosphinic acid and slowly cooled to room temperature. 4.5 g of D!-homoalanin-4-yl(methyl)phosphinic acid/cinchonine salt are obtained with an enantiomeric purity of D:L=96.7:3.3. This corresponds to an isolated yield of 96.2% of theory.
COMPARATIVE EXAMPLES
A) 90 g of tert-butanol are added to 2.7 g of DL!-homoalanin-4-yl(methyl)phosphinic acid (0.015 mole), 5.0 g of ammonium (+)-3-bromocamphor-8-sulfonate (0.015 mole) in 10 g of demineralized water at 75° C. in such a way that the temperature is kept at 75° C. The mixture is heated under reflux for 1 hour and then slowly allowed to reach room temperature. Precipitated crystals are filtered off with suction, washed and dried in vacuo at 50° C. 4.8 g of homoalanin-4-yl(methyl)phosphinic acid/(+) -3-bromocamphor-8-sulfonic acid salt are obtained with a diastereomer content of L:D=50:50.
B) 3.0 g of ammonium DL!-homoalanin-4-yl(methyl)phosphinate (0.015 mole), 5.0 g of ammonium (+)-3-bromocamphor-8-sulfonate (0.015 mole) are dissolved in 10 g of demineralized water at 75° C. and, at this temperature, 135 g of tert-butanol are added. 1.53 g of H2 SO4 (96% strength) (0.015 mole) are added, and the mixture is allowed to cool slowly. 3.5 g of homoalanin-4-yl(methyl)phosphinic acid/(+)-3-bromocamphor-8-sulfonic acid salt with a diastereomer content of L:D =50.1:49.9 are obtained.
C) 2.9 g of D!-homoalanin-4-yl(methyl)phosphinic acid/quinine salt with a D salt:L salt purity of 99.8:0.2 (0.0057 mole), 0.07 g of salicylaldehyde, 6.2 g of acetic acid and 0.02 g of water are stirred at 50° C. for 8 hours. The solution obtained in this way contains the racemic salt in a diastereomer ratio of L salt:D salt =49.8:50.2.
D) 6.2 g of quinine, 3.44 g of DL!-homoalanin-4-yl-(methyl)phosphinic acid in 20 ml of acetic acid and 80 ml of methyl isobutyl ketone are heated and slowly cooled to room temperature. During this, 3.1 g of DL! salt of diastereomer ratio L:D=49.6:50.4 crystallize out.

Claims (11)

What is claimed is:
1. A process for preparing L!-homoalanin-4-yl(methyl)-phosphinic acid (L-acid), (L-la)) or salts thereof or D!-homoalatin-4-yl(methyl)-phosphinic acid (D-acid, (D-la)) or salts thereof ##STR2## from DL!-homoalanin-4-yl(methyl)-phosphinic acid (DL-acid, DL-la)) or salts thereof by racemate solution, which comprises
a) reacting DL acid or salt thereof with a chiral base, selected from the group consisting of alkaloid bases;
b) allowing the salt of the L acid or D acid and of the chiral base to crystallize out of a solution of the resulting mixture of the disastereomeric salts of D acid, L acid and the chiral base in an aqueous or aqueous-organic solvent in which the salt of the D acid or of the L acid has a higher solubility than the salt of the L acid or D acid, respectively (racemate resolution) and
c) in the case where the free L acid or D acid is prepared, neutralizing the resulting salt with an acid, or in the case where a salt other than that obtained according to b) is prepared, carrying out a metathesis.
2. The process as claimed in claim 1, wherein L acid or salts thereof are prepared.
3. The process as claimed in claim 2, wherein quinine is used as chiral base.
4. The process as claimed in claim 3, wherein solvent mixtures of water and organic solvents from the group of alcohols and ketones are used as solvents.
5. The process as claimed in claim 4, wherein a solvent mixture of water and isopropanol or tert-butanol is used.
6. The process as claimed in claim 5, wherein stage b) is carried out at temperatures of 0°-100° C.
7. The process as claimed in claim 6, wherein the D-acid (D-Ia) or salts thereof are racemized, and the resulting racemic D-acid (D-Ia) or salt thereof is used for the racemate resolution.
8. The process as claimed in claim 7, wherein the D-acid (D-Ia) or salt thereof if racemized in the presence of six-membered (hetero)aromatic aldehydes which have a hydroxyl group in position 2 with respect to the aldehyde group and electron-attracting radicals in position 3 or 5 with respect to the aldehyde group and are further substituted where appropriate, in aqueous or aqueous-organic medium without addition of acids.
9. The process as claimed in claim 8, wherein 5-nitrosalicylaldehyde or 3,5-dinitrosalicylaldehyde is used without addition of organic acids.
10. The process as claimed in any of claim 7, wherein the racemization is carried out at temperatures of 0°-120° C.
11. The process as claimed in claim 8, wherein a mixture of the diastereomeric salts of D acid and L acid and of the chiral base, dissolved in an aqueous or aqueous-organic solvent in which the salt of D acid has a higher solubility than the salt of L acid, is reacted at temperatures of 0°-85° C. in the presence of the aldehyde, with the temperature being set sufficiently low for the salt of the L acid and of the chiral base to crystallize out at the same time.
US08/398,216 1994-03-04 1995-03-02 Processes for preparing L!- or D!-homoalanin-4-yl-(methyl)phosphinic acid and salts thereof by racemate resolution Expired - Lifetime US5767309A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/049,404 US5869668A (en) 1994-03-04 1998-03-27 Processes for preparing L!- or D!-homoalanin-4-yl-(methyl) phosphinic acid and salts thereof by racemate resolution

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4407197A DE4407197A1 (en) 1994-03-04 1994-03-04 Process for the preparation of / L / -Homoalanin-4-yl- (methyl) phosphinic acid and its salts by resolution
DE4407197.3 1994-03-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/049,404 Division US5869668A (en) 1994-03-04 1998-03-27 Processes for preparing L!- or D!-homoalanin-4-yl-(methyl) phosphinic acid and salts thereof by racemate resolution

Publications (1)

Publication Number Publication Date
US5767309A true US5767309A (en) 1998-06-16

Family

ID=6511844

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/398,216 Expired - Lifetime US5767309A (en) 1994-03-04 1995-03-02 Processes for preparing L!- or D!-homoalanin-4-yl-(methyl)phosphinic acid and salts thereof by racemate resolution
US09/049,404 Expired - Lifetime US5869668A (en) 1994-03-04 1998-03-27 Processes for preparing L!- or D!-homoalanin-4-yl-(methyl) phosphinic acid and salts thereof by racemate resolution

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/049,404 Expired - Lifetime US5869668A (en) 1994-03-04 1998-03-27 Processes for preparing L!- or D!-homoalanin-4-yl-(methyl) phosphinic acid and salts thereof by racemate resolution

Country Status (19)

Country Link
US (2) US5767309A (en)
EP (1) EP0748325B1 (en)
JP (1) JP4303785B2 (en)
CN (1) CN1053669C (en)
AT (1) ATE176475T1 (en)
AU (1) AU704175B2 (en)
BR (1) BR9506986A (en)
CA (1) CA2184718A1 (en)
CZ (1) CZ260196A3 (en)
DE (2) DE4407197A1 (en)
ES (1) ES2128717T3 (en)
FI (1) FI963422A0 (en)
HU (1) HU215583B (en)
IL (1) IL112851A (en)
MX (1) MX9603873A (en)
TR (1) TR28265A (en)
TW (1) TW293012B (en)
WO (1) WO1995023805A1 (en)
ZA (1) ZA951779B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100332399B1 (en) * 1999-02-22 2002-04-13 김경호 Process for preparative resolution of metoprolol enantiomer
WO2017151573A1 (en) 2016-03-02 2017-09-08 Agrimetis, Llc Methods for making l-glufosinate
WO2018108794A1 (en) 2016-12-15 2018-06-21 Bayer Cropscience Aktiengesellschaft Method for producing d-glufosinate or salts thereof using ephedrine
WO2018108797A1 (en) 2016-12-15 2018-06-21 Bayer Cropscience Aktiengesellschaft Method for producing l-glufosinate or the salts thereof using ephedrine
WO2019018406A1 (en) * 2017-07-18 2019-01-24 Agrimetis, Llc Methods for the purification of l-glufosinate
CN109369713A (en) * 2018-12-18 2019-02-22 山东省农药科学研究院 A kind of essence glufosinate-ammonium hydrate crystal and preparation method thereof
WO2020051188A1 (en) 2018-09-05 2020-03-12 Agrimetis, Llc Methods for improving yields of l-glufosinate
WO2020214631A1 (en) 2019-04-16 2020-10-22 Agrimetis, Llc Methods for producing crystalline l-glufosinate ammonium monohydrate
WO2022259267A1 (en) * 2021-06-11 2022-12-15 Upl Limited A method for obtaining l-glufosinate
WO2023105079A1 (en) 2021-12-10 2023-06-15 Basf Se Enzymatic decarbamoylation of glufosinate derivatives
WO2023105080A1 (en) 2021-12-10 2023-06-15 Basf Se Synthesis of glufosinate using a hydantoinase-based process

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19955283A1 (en) * 1999-11-17 2001-05-23 Aventis Res & Tech Gmbh & Co Process for the enantioselective extraction of amino acids and amino acid derivatives using racemization catalysts
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
CN106188134B (en) * 2016-07-01 2018-03-20 永农生物科学有限公司 The separation of a kind of L glufosinate-ammoniums or its salt and process for purification
US11220521B2 (en) * 2017-04-17 2022-01-11 Nahls Corporation Co., Ltd. Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these
CN110343676B (en) 2018-04-03 2020-06-23 上海弈柯莱生物医药科技有限公司 L-glutamate dehydrogenase mutant and application thereof
CN110467580B (en) * 2018-05-10 2020-11-13 华润赛科药业有限责任公司 Resolution method of Raxinard axis chiral enantiomer
CN111072718A (en) * 2018-10-19 2020-04-28 中国药科大学 Preparation method of L-glufosinate-ammonium
CN111979208B (en) 2019-05-23 2023-01-10 弈柯莱生物科技(上海)股份有限公司 L-glutamate dehydrogenase mutant and application thereof
US11555046B2 (en) 2020-07-31 2023-01-17 Upl Ltd Crystalline form of L-glufosinate ammonium salt and process for production thereof
AR123090A1 (en) * 2020-07-31 2022-10-26 Upl Ltd CRYSTALLINE FORM OF L-GLUFOSINATE AMMONIUM SALT AND PROCESS FOR ITS PRODUCTION
CN113234767B (en) * 2021-05-13 2022-05-17 永农生物科学有限公司 Method for producing solid L-glufosinate ammonium salt powder free of crystal water
WO2023236168A1 (en) * 2022-06-10 2023-12-14 江苏七洲绿色科技研究院有限公司 Crystal of l-glufosinate ammonium salt, preparation method therefor and use thereof

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3213106A (en) * 1961-11-16 1965-10-19 Ajinomoto Kk Process of racemizing optically active alpha acids
CH551945A (en) * 1970-07-16 1974-07-31 Ciba Geigy Ag D-beta-amino-beta-(3,4-dimethoxy-phenyl)-propionic acid - separated from racemate by standard methods for use as a hypotensive
DE2856260A1 (en) * 1977-12-28 1979-07-05 Meiji Seika Kaisha HERBICIDE
EP0057092A1 (en) * 1981-01-23 1982-08-04 Tanabe Seiyaku Co., Ltd. Process for racemizing an optically active alpha-amino acid or a salt thereof
US4647692A (en) * 1984-08-30 1987-03-03 Beecham Group P.L.C. Racemization and resolution of α-amino acids
EP0224880A1 (en) * 1985-12-03 1987-06-10 Hoechst Aktiengesellschaft Process for preparing L-homoalanin-4-yl(methyl)-phosphinic acids, as well as their alkyl esters
EP0238954A2 (en) * 1986-03-22 1987-09-30 Hoechst Aktiengesellschaft Process for preparing L-phosphinothricine (derivatives) and their alkyl esters
DE3706022A1 (en) * 1987-02-25 1988-09-08 Hoechst Ag Process for the racemization of optically active D-2-phenacetylamino-4-methylphosphinobutyric acid
EP0342575A2 (en) * 1988-05-20 1989-11-23 Hoechst Aktiengesellschaft Process for the racemisation of optical active D-2-N phenylacetylamino-4-methylphosphino butyric acid
EP0346658A1 (en) * 1988-05-27 1989-12-20 Hoechst Aktiengesellschaft Process for preparing phosphorus-containing L-amino acids, their esters and N-derivatives
DE3920570A1 (en) * 1989-06-23 1991-01-03 Hoechst Ag Recovery of L-2-amino-4-methyl-phosphino-butyric acid - from prod. of enzymatic trans;amination of 4-(hydroxy)(methyl) phosphinyl-2-oxo:butyric acid by stepwise acid and pptn.
DE3923650A1 (en) * 1989-07-18 1991-01-31 Hoechst Ag Isolation of L-phosphino-thricin - by electrodialysis using enzymatic transamination solns.
EP0499376A1 (en) * 1991-01-31 1992-08-19 Hoechst Celanese Corporation Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof
CA2065128A1 (en) * 1991-04-06 1992-10-07 Michael Hoffmann Process for the preparation of phosphorus-containing l-amino acids, their derivatives and intermediates for this process
EP0508298A2 (en) * 1991-04-09 1992-10-14 Siemens Aktiengesellschaft Slide switch
CA2075151A1 (en) * 1991-08-03 1993-02-04 Hans-Joachim Zeiss Optically active w-halo-2-aminoalkanecarboxylic acid derivatives, process for the preparation thereof and their use for the preparation of optically active phosphorus-containing –-amino acids
CA2085145A1 (en) * 1991-12-13 1993-06-14 Hans-Joachim Zeiss Process for the preparation of l-phosphinothricin and its derivatives
EP0546556A2 (en) * 1991-12-11 1993-06-16 Sharp Kabushiki Kaisha Electrophotographic printing machine
US5229379A (en) * 1990-06-22 1993-07-20 Ciba-Geigy Corporation Certain n-substituted-amino-alkane phosphinic acid derivatives having anti-epileptic properties
EP0382113B1 (en) * 1989-02-06 1994-09-21 Hoechst Schering AgrEvo GmbH Process for the enzymatic separation of 2-amino-4-methyl-phosphino-butyric-acid derivatives

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3213106A (en) * 1961-11-16 1965-10-19 Ajinomoto Kk Process of racemizing optically active alpha acids
CH551945A (en) * 1970-07-16 1974-07-31 Ciba Geigy Ag D-beta-amino-beta-(3,4-dimethoxy-phenyl)-propionic acid - separated from racemate by standard methods for use as a hypotensive
DE2856260A1 (en) * 1977-12-28 1979-07-05 Meiji Seika Kaisha HERBICIDE
US4265654A (en) * 1977-12-28 1981-05-05 Meiji Seika Kaisha Ltd. Herbicidal compositions
EP0057092A1 (en) * 1981-01-23 1982-08-04 Tanabe Seiyaku Co., Ltd. Process for racemizing an optically active alpha-amino acid or a salt thereof
US4647692A (en) * 1984-08-30 1987-03-03 Beecham Group P.L.C. Racemization and resolution of α-amino acids
US4777279A (en) * 1985-12-03 1988-10-11 Hoechst Aktiengesellschaft Process for the preparation of L-homoalanin-4-yl(methyl)-phosphinic acid and its alkyl esters
EP0224880A1 (en) * 1985-12-03 1987-06-10 Hoechst Aktiengesellschaft Process for preparing L-homoalanin-4-yl(methyl)-phosphinic acids, as well as their alkyl esters
US4922006A (en) * 1986-03-22 1990-05-01 Hoechst Aktiengesellschaft Process for the preparation of L-phosphinothricine (derivatives) and also of their alkyl esters
EP0238954A2 (en) * 1986-03-22 1987-09-30 Hoechst Aktiengesellschaft Process for preparing L-phosphinothricine (derivatives) and their alkyl esters
DE3706022A1 (en) * 1987-02-25 1988-09-08 Hoechst Ag Process for the racemization of optically active D-2-phenacetylamino-4-methylphosphinobutyric acid
EP0342575A2 (en) * 1988-05-20 1989-11-23 Hoechst Aktiengesellschaft Process for the racemisation of optical active D-2-N phenylacetylamino-4-methylphosphino butyric acid
EP0346658A1 (en) * 1988-05-27 1989-12-20 Hoechst Aktiengesellschaft Process for preparing phosphorus-containing L-amino acids, their esters and N-derivatives
US5374736A (en) * 1988-05-27 1994-12-20 Hoechst Aktiengesellschaft L-4-(phosphinylethyl)-1,3-oxazolidin-5-one derivatives as intermediates for synthesis of phosphorus-containing L-amino acids
EP0382113B1 (en) * 1989-02-06 1994-09-21 Hoechst Schering AgrEvo GmbH Process for the enzymatic separation of 2-amino-4-methyl-phosphino-butyric-acid derivatives
DE3920570A1 (en) * 1989-06-23 1991-01-03 Hoechst Ag Recovery of L-2-amino-4-methyl-phosphino-butyric acid - from prod. of enzymatic trans;amination of 4-(hydroxy)(methyl) phosphinyl-2-oxo:butyric acid by stepwise acid and pptn.
DE3923650A1 (en) * 1989-07-18 1991-01-31 Hoechst Ag Isolation of L-phosphino-thricin - by electrodialysis using enzymatic transamination solns.
US5229379A (en) * 1990-06-22 1993-07-20 Ciba-Geigy Corporation Certain n-substituted-amino-alkane phosphinic acid derivatives having anti-epileptic properties
EP0499376A1 (en) * 1991-01-31 1992-08-19 Hoechst Celanese Corporation Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof
CA2065128A1 (en) * 1991-04-06 1992-10-07 Michael Hoffmann Process for the preparation of phosphorus-containing l-amino acids, their derivatives and intermediates for this process
EP0508296A1 (en) * 1991-04-06 1992-10-14 Hoechst Schering AgrEvo GmbH Process for the preparation of phosphorus containing L-amino acids, their derivatives and intermediates for this process
EP0508298A2 (en) * 1991-04-09 1992-10-14 Siemens Aktiengesellschaft Slide switch
EP0530506A1 (en) * 1991-08-03 1993-03-10 Hoechst Schering AgrEvo GmbH Optically active omega-halogen-2-amino alkanoic acids derivatives, process for their preparation and their use for the preparation of optically active phosphor-containing alpha-aminoacids
CA2075151A1 (en) * 1991-08-03 1993-02-04 Hans-Joachim Zeiss Optically active w-halo-2-aminoalkanecarboxylic acid derivatives, process for the preparation thereof and their use for the preparation of optically active phosphorus-containing –-amino acids
EP0546556A2 (en) * 1991-12-11 1993-06-16 Sharp Kabushiki Kaisha Electrophotographic printing machine
CA2085145A1 (en) * 1991-12-13 1993-06-14 Hans-Joachim Zeiss Process for the preparation of l-phosphinothricin and its derivatives

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
Bull. Chim. Soc. Jap., vol. 56 (1993), pp. 3744 3747. *
Bull. Chim. Soc. Jap., vol. 56 (1993), pp. 3744-3747.
Bulletin of the Chemical Society of Japan, vol. 36, No. 6, 1963, Tokyo, Japan by Toi et al. entitled "Synthesis Resins Catalyzing the Racemization of Amino Acids. I. The Preparation of the Resins", pp. 734-738.
Bulletin of the Chemical Society of Japan, vol. 36, No. 6, 1963, Tokyo, Japan by Toi et al. entitled Synthesis Resins Catalyzing the Racemization of Amino Acids. I. The Preparation of the Resins , pp. 734 738. *
Bulletin of the Chemical Society of Japan, vol. 41, No. 9, 1969, Tokyo, Japan by M. Ando & S. Emoto entitled "Catalytic Activities of Salicylaledehyd Derivatives: II. Kinetic Studies of the Racemization of Amino Acid", pp. 2628-2631.
Bulletin of the Chemical Society of Japan, vol. 41, No. 9, 1969, Tokyo, Japan by M. Ando & S. Emoto entitled Catalytic Activities of Salicylaledehyd Derivatives: II. Kinetic Studies of the Racemization of Amino Acid , pp. 2628 2631. *
Bulletin of the Chemical Society of Japan, vol. 51, No. 8, 1978, Tokyo, Japan, by M. Ando & S. Emoto entitled "Catalytic Activities of Saliclaldehyde Derivatives VIII. Kinetic Studies of Catalytic Racemization of Glutamic Acid at 25 C", pp. 2366-2368.
Bulletin of the Chemical Society of Japan, vol. 51, No. 8, 1978, Tokyo, Japan, by M. Ando & S. Emoto entitled Catalytic Activities of Saliclaldehyde Derivatives VIII. Kinetic Studies of Catalytic Racemization of Glutamic Acid at 25 C , pp. 2366 2368. *
Chem. Lett. (1990), pp. 233 234. *
Chem. Lett. (1990), pp. 233-234.
Chemical Abstracts, vol. 68, No. 3, Jan. 15, 1968, Columbus, Ohio, Abstract No. 13342, by S. Yoshikawa et al. entitled "The Racemization of 1-Gutamic Acid by the Catalytic Action of Alicyladehyde Derivatives in the Presence of Metal Ion", pp. 331-336.
Chemical Abstracts, vol. 68, No. 3, Jan. 15, 1968, Columbus, Ohio, Abstract No. 13342, by S. Yoshikawa et al. entitled The Racemization of 1 Gutamic Acid by the Catalytic Action of Alicyladehyde Derivatives in the Presence of Metal Ion , pp. 331 336. *
Chemical Abstracts, vol. 91, No. 24, Dec. 10, 1979, Columbus, Ohio, Abstract No. 193857v by I.A. Yamskov et al. entitled "Preparation of Poly(acylamidosalicyladehyde) and the Study of its Ability to Catalyze the Racemization of Optically Active Amino Acids".
Chemical Abstracts, vol. 91, No. 24, Dec. 10, 1979, Columbus, Ohio, Abstract No. 193857v by I.A. Yamskov et al. entitled Preparation of Poly(acylamidosalicyladehyde) and the Study of its Ability to Catalyze the Racemization of Optically Active Amino Acids . *
English Language abstract of DE OS 39 20 570. *
English Language abstract of the DE OS 39 23 650. *
Gal, et al., J. Org. Chem. 42(1), 142 3, 1977. *
Gal, et al., J. Org. Chem. 42(1), 142-3, 1977.
J. Org. Chem. 1983, 48, pp. 843 846 by Yamada et al. *
J. Org. Chem. 1983, 48, pp. 843-846 by Yamada et al.
Japanese Application No. 4 213445 published Apr. 8, 1992. *
Japanese Application No. 4-213445 published Apr. 8, 1992.
Journal of the Medical Chemical Society, vol. 76, 1954, Washington, by Ikawa et al. entitled Benze Analogs of Pyridoxal. The Reactions of 4 Nitrosalicylaldehyde with Amino Acids, pp. 653 655. *
Journal of the Medical Chemical Society, vol. 76, 1954, Washington, by Ikawa et al. entitled Benze Analogs of Pyridoxal. The Reactions of 4-Nitrosalicylaldehyde with Amino Acids, pp. 653-655.

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100332399B1 (en) * 1999-02-22 2002-04-13 김경호 Process for preparative resolution of metoprolol enantiomer
US11732281B2 (en) 2016-03-02 2023-08-22 Basf Se Methods for making L-glufosinate
AU2017227553B2 (en) * 2016-03-02 2021-03-25 Basf Se Methods for making L-glufosinate
US11913048B2 (en) 2016-03-02 2024-02-27 Basf Se Methods for making L-glufosinate
US11905538B2 (en) 2016-03-02 2024-02-20 Basf Se Methods for making L-glufosinate
US10260078B2 (en) * 2016-03-02 2019-04-16 Agrimetis, Llc Methods for making L-glufosinate
WO2017151573A1 (en) 2016-03-02 2017-09-08 Agrimetis, Llc Methods for making l-glufosinate
US10781465B2 (en) 2016-03-02 2020-09-22 Agrimetis, Llc Methods for making L-glufosinate
US11560577B2 (en) 2016-03-02 2023-01-24 Basf Se Methods for making L-glufosinate
WO2018108797A1 (en) 2016-12-15 2018-06-21 Bayer Cropscience Aktiengesellschaft Method for producing l-glufosinate or the salts thereof using ephedrine
WO2018108794A1 (en) 2016-12-15 2018-06-21 Bayer Cropscience Aktiengesellschaft Method for producing d-glufosinate or salts thereof using ephedrine
US11976089B2 (en) * 2017-07-18 2024-05-07 Basf Se Methods for the purification of L-glufosinate
US11634442B2 (en) * 2017-07-18 2023-04-25 Basf Se Methods for the purification of L-glufosinate
IL271990B2 (en) * 2017-07-18 2023-05-01 Agrimetis Llc Methods for the purification of l-glufosinate
IL271990A (en) * 2017-07-18 2020-02-27 Agrimetis Llc Methods for the purification of l-glufosinate
US11897908B2 (en) 2017-07-18 2024-02-13 Basf Se Methods for the purification of L-glufosinate
US11897909B2 (en) 2017-07-18 2024-02-13 Basf Se Methods for the purification of L-glufosinate
WO2019018406A1 (en) * 2017-07-18 2019-01-24 Agrimetis, Llc Methods for the purification of l-glufosinate
WO2020051188A1 (en) 2018-09-05 2020-03-12 Agrimetis, Llc Methods for improving yields of l-glufosinate
CN109369713A (en) * 2018-12-18 2019-02-22 山东省农药科学研究院 A kind of essence glufosinate-ammonium hydrate crystal and preparation method thereof
WO2020214631A1 (en) 2019-04-16 2020-10-22 Agrimetis, Llc Methods for producing crystalline l-glufosinate ammonium monohydrate
WO2022259267A1 (en) * 2021-06-11 2022-12-15 Upl Limited A method for obtaining l-glufosinate
WO2023105079A1 (en) 2021-12-10 2023-06-15 Basf Se Enzymatic decarbamoylation of glufosinate derivatives
WO2023105080A1 (en) 2021-12-10 2023-06-15 Basf Se Synthesis of glufosinate using a hydantoinase-based process

Also Published As

Publication number Publication date
AU1759595A (en) 1995-09-18
ZA951779B (en) 1995-11-09
FI963422A (en) 1996-09-02
DE4407197A1 (en) 1995-09-07
WO1995023805A1 (en) 1995-09-08
FI963422A0 (en) 1996-09-02
IL112851A0 (en) 1995-06-29
EP0748325B1 (en) 1999-02-03
IL112851A (en) 2000-08-13
BR9506986A (en) 1997-09-16
HUT75050A (en) 1997-03-28
CA2184718A1 (en) 1995-09-08
MX9603873A (en) 1997-03-29
ATE176475T1 (en) 1999-02-15
JP4303785B2 (en) 2009-07-29
AU704175B2 (en) 1999-04-15
HU9602411D0 (en) 1996-11-28
TW293012B (en) 1996-12-11
TR28265A (en) 1996-04-09
US5869668A (en) 1999-02-09
EP0748325A1 (en) 1996-12-18
JPH09509924A (en) 1997-10-07
HU215583B (en) 1999-01-28
CZ260196A3 (en) 1997-02-12
CN1143369A (en) 1997-02-19
CN1053669C (en) 2000-06-21
DE59505034D1 (en) 1999-03-18
ES2128717T3 (en) 1999-05-16

Similar Documents

Publication Publication Date Title
US5767309A (en) Processes for preparing L!- or D!-homoalanin-4-yl-(methyl)phosphinic acid and salts thereof by racemate resolution
ES2214047T3 (en) PROCEDURE FOR DISOCIATION OF 2-HYDROXIPROPIONIC ACIDS RACEMATES.
US4319040A (en) Process for the production of optically active threo-3-(3,4-dihydroxyphenyl)serine
CZ281203B6 (en) Process for preparing optically active amino acid amides, intermediates therefor and use
EP0499376A1 (en) Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof
US4647692A (en) Racemization and resolution of α-amino acids
EP0937705B1 (en) Process for preparing D-alloisoleucine and intermediates for preparation
KR100671084B1 (en) Process for preparing [l]- or [d]-homoalanin-4-yl-(methyl)phosphinic acid and its salts by racemic resolution
EP1912931A2 (en) Preparation of (s)-pregabalin-nitrile
EP0070114B1 (en) A process for preparing an optically active p-hydroxyphenyl-glycine or a salt thereof
JP4138928B2 (en) Method for producing D-alloisoleucine and intermediate for production
Drauz et al. Synthesis of (R)‐tert‐leucinol by classical resolution of the racemic mixture
US4285884A (en) Process for resolution of racemic DL-α-aminocarboxylic acids
JPH07149688A (en) Method for optical resolution of 2-arylpropionic acid compound
WO1985003932A1 (en) Novel diastereomer salts of phenylalanine and n-acyl derivatives thereof and process for the separation of optically active phenylalanine and n-acyl derivatives thereof
EP0253571B1 (en) Process for resolution and race mization of amines with acidic alpha-hydrogens
JPH052665B2 (en)
SK19002001A3 (en) Method for separating the diastereomer bases of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol
JPH05148278A (en) Resolution of racemic modification
US6172259B1 (en) Production of enantiomer-free biarylketocarboxylic acids
JPH021446A (en) Preparation of n-hydroxy-alpha-amino acid and its derivative, and compound thus obtained
US5760287A (en) Process for the resolution of 6-methoxy-alpha-methyl-2-naphthaleneacetic racemic acid into its enantiomers
EP1264814A1 (en) Resolving agents based on amines
JPH0470306B2 (en)
JPH10101633A (en) Production of optically active amino acid ester having high optical purity

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOECHST SCHERING AGREVO GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KNORR, HARALD;SCHLEGEL, GUNTER;STARK, HERBERT;REEL/FRAME:007491/0413

Effective date: 19950220

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: BAYER CROPSCIENCE GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS CROPSCIENCE GMBH;REEL/FRAME:021924/0762

Effective date: 20020605

Owner name: BAYER CROPSCIENCE AG, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BAYER CROPSCIENCE GMBH;REEL/FRAME:021838/0869

Effective date: 20070413

Owner name: AVENTIS CROPSCIENCE GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:HOECHST SCHERING AGREVO GMBH;REEL/FRAME:021824/0729

Effective date: 19991230

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CROPSCIENCE AG;REEL/FRAME:034914/0354

Effective date: 20130722